NDA 205437 · Amgen INC
Otezla
Apremilast · Oral · Phosphodiesterase 4 Inhibitor
NovelOrphanLast checked: Nov 19, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Mar 21, 2014
Approved uses
7
Original approval plus efficacy supplements
Registered trials
139
40 Phase 3, 12 recruiting
FAERS reports
146,435
35,036 serious, 6,208 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 2, 2026.
OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis ( 1.1 ) Plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Oral ulcers associated with Behçet's Disease ( 1.3 ) Pediatric patients 6 years of age and older with: Active psoriatic arthritis ( 1.1 ) Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) In the pediatric population, OTEZLA is indicated for patients weighing at least 20 kg, and OTEZLA XR is indicated for patients weighing at least 50 kg. 1.1 Psoriatic Arthritis OTEZLA is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis. OTEZLA XR is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis. 1.2 Plaque Psoriasis OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA XR is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.3 Oral Ulcers Associated with Behçet's Disease OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease.
Mechanism: Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2025 Supplement 14 · Efficacy OrphanLetterLabel
- Apr 25, 2024 Supplement 13 · Efficacy · priority review OrphanLetterLabel
- Jul 20, 2023 Supplement 12 · Efficacy OrphanLetterLabel
- Dec 20, 2021 Supplement 11 · Efficacy LetterLabelReview
- Apr 10, 2020 Supplement 8 · Efficacy LetterLabel
- Jul 19, 2019 Supplement 7 · Efficacy OrphanLabelLetterReview
- Mar 21, 2014 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
3 products under this application
- OTEZLA · APREMILAST 30MG · TABLET, ORAL · Prescription · TE AB
- OTEZLA · APREMILAST 10MG · TABLET, ORAL · Prescription · TE AB
- OTEZLA · APREMILAST 20MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Apremilast" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT06108544 · 1,108 participants · Start Nov 6, 2023 · Primary completion Dec 6, 2024
Drug: TAK-279; Placebo and 1 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Hoover, Alabama; Phoenix, Arizona · 217 sites in all
- An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03611751 · 1,020 participants · Start Jul 26, 2018 · Primary completion Nov 29, 2020
Drug: BMS-986165; Apremilast · For: Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tempe, Arizona · 205 sites in all
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Alumis IncIndustry
NCT06586112 · 912 participants · Start Jul 25, 2024 · Primary completion Sep 19, 2025
Drug: Envudeucitinib; Apremilast and 1 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Rogers, Arkansas · 156 sites in all
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001Pivotal-lookingCompleted
Alumis IncIndustry
NCT06588738 · 862 participants · Start Aug 20, 2024 · Primary completion Sep 23, 2025
Drug: Envudeucitinib; Placebo and 1 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 124 sites in all
- Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01194219 · 844 participants · Start Sep 9, 2010 · Primary completion Feb 23, 2012
Drug: Apremilast; Placebo and 1 more · For: Plaque Psoriasis
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04908189 · 729 participants · Start Jul 15, 2021 · Primary completion Nov 7, 2024
Drug: Deucravacitinib; Apremilast · For: Psoriatic Arthritis
Sites: Mountain Brook, Alabama; Sacramento, California; Whittier, California · 138 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea24,755
- nausea22,292
- psoriasis20,666
- headache18,012
- drug ineffective15,674
- abdominal discomfort8,337
- psoriatic arthropathy8,315
- pain7,045
- rash6,888
- vomiting6,639
- arthralgia6,531
- fatigue6,327
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 1,244 |
| 2015 | 12,439 |
| 2016 | 13,932 |
| 2017 | 18,313 |
| 2018 | 19,926 |
| 2019 | 22,848 |
| 2020 | 19,781 |
| 2021 | 10,551 |
| 2022 | 7,338 |
| 2023 | 5,928 |
| 2024 | 6,024 |
| 2025 | 4,946 |
| 2026 | 3,158 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Otezla (Apremilast)
2024 spending
$1.05B
Beneficiaries
31,045
213,396 claims
Per beneficiary
$33,662
$80.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $488,493,382 |
| 2021 | $582,336,333 |
| 2022 | $710,069,159 |
| 2023 | $876,955,030 |
| 2024 | $1,045,029,751 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of pediatric alopecia areata: A systematic review.
Barton VR, Toussi A, Awasthi S, et al. · J Am Acad Dermatol 2022 · Systematic Review, Research Support, N.I.H., Extramural
- EULAR recommendations for the management of Behçet's syndrome: 2025 update.
Hatemi G, Ramiro S, Ozguler Y, et al. · Ann Rheum Dis 2026 · Consensus Statement, Practice Guideline
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, et al. · J Am Acad Dermatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Treatments for alopecia areata: a network meta-analysis.
Mateos-Haro M, Novoa-Candia M, Sánchez Vanegas G, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.